Insulin-like growth factor-I for the treatment of type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 2, Issue 6, 2000, Pages 335-343

  Acerini, Carlo L ^a   Dunger, David B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE BINDING PROTEIN; INSULIN; PROINSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ARTHRALGIA; BELL PALSY; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; FACE EDEMA; FATIGUE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MYALGIA; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; TACHYCARDIA;

EID: 0034525221     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00123.x     Document Type: Review

References (80)

1. Antibody suppressible and non-suppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity
2. Sequence of cDNA encoding human insulin-like growth factor-1 precursor
3. The amino acid sequence of human insulin-like growth factor 1 and its structural homology with proinsulin
4. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidemal growth factor
5. Insulin-like growth factors I and II
6. Insulin-like growth factor 1 receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity
7. Effects of insulin-like growth factor 1 on the rates of glucose transport and utilization in rat skeletal muscle in vitro
8. Effects of in-vivo administration of insulin-like growth factor-1 on the rate of glucose utilization in the soleus muscle of the rat
9. How does the mitogenic insulin-like growth factor-1 receptor differ from the metabolic insulin receptor?
10. IRS-I is a common element of insulin and IGF-I signalling to the phosphatidylinositol 3′-kinase
11. Hybrid and atypical insulin-like growth factor receptors
12. Differential signalling potential of insulin- and IGF-1 receptor cytoplasmic domains
13. Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action
14. Recomendations for nomenclature of the insulin-like growth factor binding protein superfamily
15. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): Characterization of connective tissue growth factor as a member of the IGFBP superfamily
16. Insulin-like growth factor (IGF) and IGF-binding proteins: Comparison of human serum and lymph
17. Measurement of free insulin-like growth factor-1 using immunoradiometric assay
18. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150k complex during pregnancy
19. Insulin-like growth factor binding protein-3 proteolyis is induced after elective surgery
20. Low serum somatomedin-c in insulin-dependent diabetes: Evidence for a postreceptor mechanism
21. Growth hormone receptor and serum binding protein: Cloning and expression
22. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-1 (IGF-1), and IGF-1 receptors in obesity and anorexia nervosa
23. Insulin and variation in glucose levels modify the secretion rates of growth hormone independent insulin-like growth factor binding protein-1 in the human hepatoblastoma cell line Hep G2
24. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: A new role for insulin?
25. Insulin-like growth factor-binding protein-1: A role in glucose counterregulation?
26. Insulin-like growth factor protein-3 proteolysis in children with insulin dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity
27. Short-term metabolic effects of recombinant human insulin-like growth factor 1 in healthy adults
28. Effect of increasing doses of recombinant human insulin-like growth factor-1 on glucose, lipid and leucine metabolism in man
29. Diverse effects of insulin-like growth factor 1 on glucose, lipid, and amino acid metabolism
30. Insulin-like growth factor 1 binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver
31. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats
32. Differential effects of IGF-1 and insulin on glucoregulation and fat metabolism in depancreatised dogs
33. Acute effects of insulin-like growth factor 1 on glucose and amino acid metabolism in the awake fasted rat
34. Metabolic effects of insulin-like growth factor 1 in normal humans
35. Insulin-like growth factor binding protein-1 modulates blood glucose levels
36. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin dependent diabetes
37. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: Possible contribution of insulin-like growth factor binding protein-1
38. Insulin-like growth factor 1 stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans
39. Somatomedin-C/IGF-1 measured by immunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls
40. Insulin-like growth factor binding protein-1 levels in diabetic adolescents and their relationship to metabolic control
41. Insulin therapy increases low plasma growth hormone binding protein in children with new onset type 1 diabetes
42. Serum levels of growth hormone-binding protein and insulin-like growth factor 1 in children and adolescents with type 1 (insulin dependent) diabetes mellitus
43. Loss of the normal relationships between growth hormone, growth hormone binding protein and insulin-like growth factor-1 in adolescents with insulin-dependent diabetes mellitus
44. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3 and IGF-1 in insulin-dependent diabetes
45. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary
46. Insulin like growth factor-1 regulation of growth hormone gene transcription in primary rat pituitary cells
47. Characterization of the insulin-antagonistic effect of growth hormone in man
48. Increased overnight growth hormone concentrations in diabetics compared with normal adolescents
49. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics
50. Evidence for a role for insulin and growth hormone in the overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents
51. Diabetes in puberty
52. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes
53. Effect of diabetes and its control on insulin like growth factors in the young subject with type 1 diabetes
54. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients
55. Does recombinant insulin-like growth factor 1 have a role in the treatment of insulin-dependent diabetes mellitus during adolescence?
56. The effects of recombinant insulin-like growth factor 1 administration on growth hormone levels and insulin requirements in adolescents with Type 1 (insulin dependent) diabetes mellitus
57. Pharmacokinetic profile of recombinant human insulin-like growth factor 1 given subcutaneously in normal subjects
58. The effects of subcutaneous insulin-like growth factor-1 infusion in insulin-dependent diabetes mellitus
59. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor 1 (rhIGF-1)
60. Effects of low-dose recombinant human insulin-like growth factor-1 on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus
61. Mediation of the hepatic effects of growth hormone by its lipolytic activity
62. The effects of recombinant human IGF-1 administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-1, IGF-1I and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus
63. The effects of repeated daily recombinant human insulin-like growth factor 1 administration in adolescents with type 1 diabetes
64. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor 1 in IDDM. Effects on glycemic control, IGF-1 levels, and safety profile
65. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycemic control in type 1 diabetes
66. RhIGF-1 administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM
67. Randomised placebo-controlled trial of human recombinant insulin-like growth factor 1 plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus
68. Adverse effects of recombinant human insulin-like growth factor 1 in obese insulin resistant type 1 diabetic patients
69. Safety profiling of rhIGF-1 therapy in patients with NIDDM. A dose ranging, placebo controlled trial
70. Normoglycaemic re-entry and diabetic complications
71. Insulin-like growth factors. Studies in diabetics with and without retinopathy
72. Insulin-like growth factor 1 acts as an agent in rabbit cornea and retina: Comparative studies with basic fibroblast growth factor
73. Does insulin-like growth factor 1 predict incidence and progression of diabetic retinopathy?
74. Role of growth hormone in diabetes mellitus
75. The role of growth hormone in the development of diabetic retinopathy
76. Is insulin-like growth factor associated with diabetic retinopathy
77. Free and total insulin-like growth factor 1 (IGF-1), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus
78. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy
79. Cancelled IGF-1 trials bode ill for diabetic patients
80. The combination of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin dependent Type-1 diabetes: Evidence for in vivo biological activity